Are clofazimine-based regimens safe regarding QTc prolongation in patients with drug-resistant TB?
Emphasizes the need for active drug safety monitoring for QTc prolongation in patients treated with newly recommended clofazimine-based regimens for drug-resistant TB.
In June 2024, WHO released 'Key updates to the treatment of drug-resistant tuberculosis: rapid communication', after the preliminary publication of results from two clinical trials: 'BEAT-Tuberculosis' and 'endTB'. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported a high incidence of QTc prolongation among patients receiving Cfz-based treatment for multidrug-resistant TB in Taiwan. Here, we discuss the cardiac safety of Cfz and the role of active drug safety monitoring at the programme level in collecting information on this issue.
Pontali et al. (Fri,) studied this question.